Figure 3.

Adjusted risk of HRT (testosterone in males; estrogen/progesterone in females) on 90-day outcomes after COVID-19 diagnosis in (A) the nonimmunosuppressed general population and (B) solid organ transplant recipients. AKI, acute kidney injury; COVID-19, coronavirus disease 2019; HR, hazard ratio; HRT, hormone replacement therapy; MACE, major adverse cardiac event; MARCE, major adverse renal or cardiac event; OR, odds ratio; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. ∗Odds ratio, ∗∗Adjusted for age, sex, race, time since transplant, type of organ transplant (kidney, liver, heart, lung, multiorgan), comorbidities (chronic kidney disease, hypertension, diabetes, chronic obstructive pulmonary disease/asthma, cancer, coronary artery disease, congestive heart failure, peripheral vascular disease, liver disease, and obesity [body mass index >30 kg/m²]), immunosuppression (antithymocyte globulin induction, basiliximab induction, and maintenance therapy with prednisone, tacrolimus, cyclosporine, or mycophenolic acid), prior COVID-19 vaccination status, and SARS-CoV-2 variant dominance period.